Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 17Melanoma 5Triple Negative Breast Neoplasms 4Small Cell Lung Carcinoma 4Neoplasms 4Carcinoma, Renal Cell 4Carcinoma, Hepatocellular 4Breast Neoplasms 4Urinary Bladder Neoplasms 3Mesothelioma, Malignant 2Head and Neck Neoplasms 2Gastrointestinal Neoplasms 2Carcinoma, Merkel Cell 2Uterine Cervical Neoplasms 1Urologic Neoplasms 1Stomach Neoplasms 1Small Cell Lung Cancer Recurrent 1Safety Issues 1Recurrent Liver Cancer After Liver Transplantation 1Recurrence 1Radiation Pneumonitis 1Ovarian Neoplasms 1Neoplasms, Squamous Cell 1Neoplasm Metastasis 1Lymphoma 1Lung Neoplasms 1Locally Advanced or Metastatic Solid Tumors 1Liver Neoplasms 1Kidney Neoplasms 1Hodgkin Disease 1

Interventions

atezolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Safety Issues × atezolizumab × Clear all
NCT03620435 2018-08-13

Trimodal Therapy Plus Atezolizumab in Muscle-invasive Bladder Cancer

McGill University Health Centre/Research Institute of the McGill University Health Centre

Phase 2 Unknown
25 enrolled

Safety Issues

Data powered by HemOnc (CC BY 4.0) Colophon âš¡